Having trouble accessing articles? Reset your cache.

Tarceva erlotinib: Phase III data

The open-label, Chinese Phase III OPTIMAL trial in 165 chemotherapy-naïve NSCLC patients with activating EGFR mutations showed that 150 mg once-daily oral Tarceva met the primary endpoint of

Read the full 282 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE